CONCLUSION
The study findings illustrate a higher bioavailability of the developed 10 mg/mL oral suspension dosage form compared to the 50mg tablet and exemplify that not all liquid 6-MP formulations are equal in terms of bioavailability of the parent drug. A starting dose 20% lower than the tablet formulation is proposed based on model informed dose optimization. Switching to PFOS can minimize sub-therapeutic or toxic exposures. However, dose modifications should be anticipated to maintain treatment intensity with close monitoring of the patient for blood counts and liver enzymes. The simulated exposures of 6MP according to the adjusted dosage regimens recommended model must be validated in real-time clinical conditions.